Evaluation of IL-2, IL-6, IL-8 and IL-10 in malignant melanoma diagnostics

Anticancer Research

Volumn 35, Issue 6, 2015, Pages 3537-3541

  Kucera, Radek ^a   Topolcan, Ondrej ^a   Treskova, Inka ^b   Kinkorova, Judita ^a   Windrichova, Jindra ^a   Fuchsova, Radka ^a   Svobodova, Sarka ^a   Treska, Vladislav ^a   Babuska, Vaclav ^b   Novak, Jaroslav ^a   Smejkal, Jiri ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Breslow score; Interleukin; Melanoma; Sentinel node

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SURGERY; CANCER THERAPY; CARCINOGENESIS; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC TEST; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEASUREMENT ACCURACY; MELANOMA; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENTINEL LYMPH NODE METASTASIS; ADOLESCENT; BLOOD; CANCER STAGING; EARLY DIAGNOSIS; FEMALE; LYMPH NODE METASTASIS; MALE; PATHOLOGY; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; EARLY DETECTION OF CANCER; FEMALE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-6; INTERLEUKIN-8; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY;

EID: 84931303930     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Spatz A, Stock N, Batist G and van Kempen LC: The biology of melanoma prognostic factors. Discov Med 10(50): 87-93, 2010.
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and Bray F: Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer 49(6): 1374-1403, 2013.
3. Anestakis D, Petanidis S, Kalyvas S, Nday CM, Tsave O, Kioseoglou E and Salifoglou A: Mechanisms and Applications of Interleukins in Cancer Immunotherapy. Int J Mol Sci 16(1): 1691-1710, 2015.
4. Bindon C, Czerniecki M, Ruell P, Edwards A, McCarthy WH, Harris R and Hersey P: Clearance rates and systemic effects of intravenously administered interleukin 2 (IL-2) containing preparations in human subjects. Br J Cancer 47(1): 123-133, 1983.
5. Weidmann E, Bergmann L, Stock J, Kirsten R and Mitrou PS: Rapid cytokine release in cancer patients treated with interleukin-2. J Immunother 12(2): 123-131, 1992.
6. Oda K and Kitano H: A comprehensive map of the toll-like receptor signaling network. Mol Syst Biol 18(2): 2006.0015, 2006.
7. Dummer W, Becker JC, Schwaaf A, Leverkus M, Moll T and Bröcker EB: Elevated serum levels of interleukin-10 in patients with metastatic melanoma. Melanoma Res 5(1): 67-68, 1995.
8. Lázár-Molnár E, Hegyesi H, Tóth S and Falus A: Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 12(6): 547-554, 2000.
9. Breslow A: Prognostic factors in the treatment of cutaneous melanoma. J Cutan Pathol 6(3): 208-212, 1979.
10. Abbasi NR, Shaw HM, Rigel DS, Friedman RJ, McCarthy WH, Osman I, Kopf AW and Polsky D: Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA 292(22): 2771-2776, 2004.
11. Kucera R, Treskova I, Vrzalova J, Svobodova S, Topolcan O, Fuchsova R, Rousarova M, Treska V and Kydlicek T: Evaluation of IGF1 serum levels in malignant melanoma and healthy subjects. Anticancer Res 34(9): 5217-5220, 2014.
12. Gaffen SL and Liu KD: Overview of interleukin-2 function, production and clinical applications. Cytokine 28(3): 109-123, 2004.
13. Rosenberg SA: IL-2: the first effective immunotherapy for human cancer. J Immunol 192(12): 5451-5458, 2014.
14. Gerber SA, Sorensen EW, Sedlacek AL, Lim JY, Skrombolas D, Frelinger JG and Lord EM: Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and long-term tumour dormancy. Immunology 138(3): 280-292, 2013.
15. Forones NM, Mandowsky SV and Lourenço LG: Serum levels of interleukin-2 and tumor necrosis factor-alpha correlate to tumor progression in gastric cancer. Hepatogastroenterology 48(40): 1199-1201, 2001.
16. Orditura M, Romano C, De Vita F, Galizia G, Lieto E, Infusino S, De Cataldis G and Catalano G: Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival. Cancer Immunol Immunother 49(10): 530-536, 2000.
17. Rath T, Billmeier U, Waldner MJ, Atreya R and Neurath MF: From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis. Arch Toxicol 30(1): 1461-1465, 2015.
18. Li Y, de Haar C, Chen M, Deuring J, Gerrits MM, Smits R, Xia B, Kuipers EJ and van der Woude CJ: Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut 59(2): 227-235, 2010.
19. Yurkovetsky ZR, Kirkwood JM, Edington HD, Marrangoni AM, Velikokhatnaya L, Winans MT, Gorelik E and Lokshin AE: Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res 13(8): 2422-2428, 2007.
20. Mashiah J, Brenner S, Pessach Y, Barak V and Schachter J: Differences in cytokine levels in melanoma patients with and without redness (Brenner sign). Anticancer Res 29(5): 1793-1796, 2009.
21. Tas F, Oguz H, Argon A, Duranyildiz D, Camlica H, Yasasever V and Topuz E: The value of serum levels of IL-6, TNF-alpha, and erythropoietin in metastatic malignant melanoma: serum IL-6 level is a valuable prognostic factor at least as serum LDH in advanced melanoma. Med Oncol 22(3): 241-246, 2005.
22. Hoejberg L, Bastholt L, Johansen JS, Christensen IJ, Gehl J and Schmidt H: Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma. Melanoma Res 22(4): 287-293, 2012.
23. Soubrane C, Rixe O, Meric JB, Khayat D and Mouawad R: Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study. Melanoma Res 15(3): 199-204, 2005.
24. Sanmamed MF, Carranza-Rua O, Alfaro C, Oñate C, Martín-Algarra S, Perez G, Landazuri SF, Gonzalez A, Gross S, Rodriguez I, Muñoz-Calleja C, Rodríguez-Ruiz M, Sangro B, López-Picazo JM, Rizzo M, Mazzolini G, Pascual JI, Andueza MP, Perez-Gracia JL and Melero I: Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins. Clin Cancer Res 20(22): 5697-5707, 2014.
25. Lattanzio L, Tonissi F, Torta I, Gianello L, Russi E, Milano G, Merlano M and Lo Nigro C: Role of IL-8 induced angiogenesis in uveal melanoma. Invest New Drugs 31(5): 1107-1111, 2013.
26. Zhang H, Fu T, McGettigan S, Kumar S, Liu S, Speicher D, Schuchter L and Xu X: IL-8 and cathepsin B as melanoma serum biomarkers. Int J Mol Sci 12(3): 1505-1518, 2011.
27. Dennis KL, Blatner NR, Gounari F and Khazaie K: Current status of interleukin-10 and regulatory T-cells in cancer. Curr Opin Oncol 25(6): 637-645, 2013.
28. Guida M, Riccobon A, Biasco G, Ravaioli A, Casamassima A, Freschi A, Palma MD, Galligioni E, Nortilli R, Chiarion-Sileni V, Picozzo J, Romanini A, Nanni O and Ridolfi R: Italian Melanoma Intergroup (IMI). Basal level and behaviour of cytokines in a randomized outpatient trial comparing chemotherapy an biochemotherapy in metastatic melanoma. Melanoma Res 16(4): 317-323, 2006.
29. Torisu-Itakura H, Lee JH, Huynh Y, Ye X, Essner R and Morton DL: Monocyte-derived IL-10 expression predicts prognosis of stage IV melanoma patients. J Immunother 30(8): 831-838, 2007.
30. Mahipal A, Terai M, Berd D, Chervoneva I, Patel K, Mastrangelo MJ and Sato T: Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine. Cancer Immunol Immunother 60(7): 1039-1045, 2011.